Why Pluristem Therapeutics Is Poised to Plunge
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Pluristem Therapeutics has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Pluristem and see what CAPS investors are saying about the stock right now.
Pluristem facts
Headquarters (founded) | Haifa, Israel (2001) |
Market Cap | $198.6 million |
Industry | Biotechnology |
Trailing-12-Month Revenue | $757 thousand |
Management | Chairman/CEO Zami Aberman |
Return on Equity (average, past 3 years) | (73%) |
Cash/Debt | $68.3 million / $0 |
Competitors | Aastrom Biosciences |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 81% of the 15 All-Star members who have rated Pluristem believe the stock will underperform the S&P 500 going forward.
One of those Fools, biotech expert zzlangerhans, tapped yesterday's 7% stock price spike as particularly unsustainable:
Wow, Pluristem received approval in Germany! Approval to run a phase II trial there, that is. Pluristem CEO seems to be aware that issuing any PR with the word "approval" somewhere in it is good for a momentary 10% spike in share price. Someone should do a study to determine the correlation between these types of announcements and the lockup expiration dates for their dilutive financings.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Pluristem Therapeutics Is Poised to Plunge originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
